OSAKA — Fujisawa Pharmaceutical Co. said Wednesday it has signed a licensing agreement with Dutch medical technology group Jomed NV in the field of medical equipment for treating cardiac disease.

Under the agreement, Fujisawa will give Jomed access to its immunosuppressant products. The Dutch firm will then develop new medical equipment coated with Fujisawa’s products.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.